Stock Price Movements, Conference Presentation Schedules, and Expanded Sharing
of Clinical Data - Research Report on Gilead, Express Scripts, Sanofi,
Agilent, and Kythera Biopharma
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, January 8, 2014
NEW YORK, January 8, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Gilead
Sciences, Inc. (NASDAQ: GILD), Express Scripts Holding Company (NASDAQ: ESRX),
Sanofi SA (ADR) (NYSE: SNY), Agilent Technologies Inc. (NYSE: A) and Kythera
Biopharmaceuticals Inc. (NASDAQ: KYTH). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.
Gilead Sciences, Inc. Research Report
On January 3, 2014, Gilead Sciences, Inc.'s (Gilead) stock declined 1.18%,
ending the day's trading session at $74.32. Over the previous three trading
sessions, shares of Gilead declined 1.01%, compared to the Nasdaq Composite
Index, which declined 0.54% during the same period. The Full Research Report
on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
Express Scripts Holding Company Research Report
On January 3, 2014, Express Scripts Holding Company (Express Scripts)
announced that the Company is scheduled to make a presentation at the J.P.
Morgan Healthcare Conference on January 15, 2014 at 8:00 a.m. PT (11:00 a.m.
ET) at the Westin St. Francis in San Francisco, California. The Company added
that interested parties may view a live broadcast of the presentation by
visiting the investor relations section of Express Scripts' website. According
to the Company, the presentation will also be archived and made available for
replay for 14 days. The Full Research Report on Express Scripts Holding
Company - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:
Sanofi SA Research Report
On January 2, 2014, Sanofi SA (Sanofi) reported that it will expand access to
information and data from clinical trials, sponsored by companies of the
Sanofi group, beginning from January 2014. According to the Company, this move
of Sanofi comes in support of industry-wide efforts to promote a set of
Principles for Responsible Sharing of Clinical Data that the Pharmaceutical
Research and Manufacturers of America (PhRMA) and the European Federation of
Pharmaceutical Industries and Associations (EFPIA), jointly released in July
2013. The Company said that it will provide access to clinical trial data and
related documents, including Clinical Study Reports (CSR), for studies
sponsored by Sanofi companies that conduct clinical studies in humans. Sanofi
stated that the studies must have been submitted to U.S. and E.U. regulatory
agencies and the product must have been approved by both agencies on or after
January 1, 2014, while for Sanofi Pasteur, the product must have been approved
by either agency on or after January 1, 2014. The Company added that it will
continue to submit for publication of the results from all company-sponsored
clinical studies, regardless of outcome. Further, Sanofi said it is working
with the regulators to adopt mechanisms so that clinical study sponsors will
be able to provide lay language summary results directly to participating
individuals. The Full Research Report on Sanofi SA (ADR) - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
Agilent Technologies Inc. Research Report
On January 3, 2014, Agilent Technologies Inc. (Agilent) announced that the
Company's President and CEO, Bill Sullivan will make a presentation at the
32^nd Annual J.P. Morgan Healthcare Conference, to be held in Westin St.
Francis Hotel, San Francisco, California on January 13, 2014 at 9:00 a.m. PT.
The Company added that interested parties may view a webcast of the
presentation via links provided at the Company's website. The Full Research
Report on Agilent Technologies Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
Kythera Biopharmaceuticals Inc. Research Report
On January 3, 2014, Kythera Biopharmaceuticals Inc.'s (Kythera
Biopharmaceuticals) stock declined 4.29%, ending the day's trading session at
$35.70. Over the previous three trading sessions, shares of Kythera
Biopharmaceuticals declined 6.30%, compared to the Nasdaq Composite Index,
which declined 0.54% during the same period. The Full Research Report on
Kythera Biopharmaceuticals Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE Analysts' Corner
Contact: Joe Thomas, +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.